ROSIPTOR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H35NO2
Molecular Weight	321.4974
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]3(C)CC[C@H](O)C[C@@H]3CO

InChI

InChIKey=MDEJTPWQNNMAQF-BVMLLJBZSA-N

InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H35NO2
Molecular Weight	321.4974
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800033407 | https://www.pharmacompass.com/product-in-pipeline/aquinox-pharmaceuticals/aqx-1125 | https://www.ncbi.nlm.nih.gov/pubmed/25040039 | http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-announces-topline-results-phase-3-leadership-301 | https://www.ncbi.nlm.nih.gov/pubmed/28658529

Rosiptor (AQX-1125) is a once daily, orally administered small molecule being developed by Aquinox Pharmaceuticals for the treatment of asthma, bladder pain syndrome/interstitial cystitis (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome. AQX-1125 is the only clinical-stage, orally administered, SHIP1 activator. AQX-1125 significantly reduces the late response to allergen challenge, with a trend to reduce airway inflammation. AQX-1125 was safe and well tolerated and merits further investigation in inflammatory disorders. AQX-1125 has been used in trials studying the treatment of COPD, atopic dermatitis, interstitial cystitis, and bladder pain syndrome. However, the development has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.	2013 Mar	23121445
Current Pharmacologic Approaches in Painful Bladder Research: An Update.	2017 Dec	29298474

Patents

Sample Use Guides

In Vivo Use Guide

AQX-1125 (450 mg daily) was administered orally for 7 days.

Route of Administration: Oral

In Vitro Use Guide

At 0.1 uM AQX-1125 the inhibition amounted to an average of 34%, while at 10 uM the inhibition amounted to an average of 82% in two independent experiments. Similarly, AQX-1125 exerted a dose-dependent inhibition of Akt phosphorylation in SHIP+/+mouse splenic lymphocytes, with a maximal inhibitory effect at 30 uM amounting to 73% and 82% in T-cells and B cells, respectively as measured by Luminex analysis

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:39:49 GMT 2023` Edited by `admin` on `Sat Dec 16 08:39:49 GMT 2023`
Record UNII	6R5034F862
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROSIPTOR

Official Name

English

(1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1- METHYLENEOCTAHYDRO -1H - INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL

Systematic Name

English

AQX-1125

Code

English

AQX-1125 FREE BASE

Code

English

Rosiptor [WHO-DD]

Common Name

English

CYCLOHEXANEMETHANOL, 2-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)OCTAHYDRO-7A-METHYL-1-METHYLENE-1H-INDEN-5-YL)-5-HYDROXY-2-METHYL-, (1S,2R,5S)-

Systematic Name

English

7-Amino-17-methylidene-6,7-seco-5α-androstane-3β,6-diol

Systematic Name

English

ROSIPTOR [USAN]

Common Name

English

rosiptor [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1404